Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NC-6004 plus gemcitabine in advanced solid tumors, squamous NSCLC, biliary tract cancer, and bladder cancer
2016-000084-16Phase 2Completed
- Sponsor
- NanoCarrier Co., Ltd.
- Start
- Oct 2016
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of demplatin pegraglumer and gemcitabine in Nonhematologic neoplasms, Pulmonary squamous cell carcinoma, biliary cancer and 5 more (4 arms), sponsored by NanoCarrier Co., Ltd. Primary endpoint: Progression-free survival. Started Oct 2016; status: completed.
02
Drugs
demplatin pegraglumergemcitabine
03
Conditions
Nonhematologic neoplasmsPulmonary squamous cell carcinomabiliary cancerbladder cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2016-000084-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000084-16.